Sponsor: Inez Lam ClearMask, LLC 1824 Webster St Baltimore, MD 21230

Synthetic Blood Penetration Resistance Final Report

CM001T-FDA-TEST-50 Test Article:

Purchase Order: P0003

Study Number:

1282245-S01

Study Received Date: 28 Mar 2020

Testing Facility: Nelson Laboratories, LLC

6280 S. Redwood Rd.

Salt Lake City, UT 84123 U.S.A.

Test Procedure(s):

Standard Test Protocol (STP) Number: STP0012 Rev 09

Deviation(s): None

Summary: This procedure was performed to evaluate surgical facemasks and other types of protective clothing materials designed to protect against fluid penetration. The purpose of this procedure is to simulate an arterial spray and evaluate the effectiveness of the test article in protecting the user from possible exposure to blood and other body fluids. The distance from the target area surface to the tip of the cannula is 30.5 cm. A test volume of 2 mL of synthetic blood was employed using the targeting plate method.

This test method was designed to comply with ASTM F1862 and ISO 22609 (as referenced in EN 14683:2019 and AS4381:2015) with the following exception: ISO 22609 requires testing to be performed in an environment with a temperature of 21 ± 5°C and a relative humidity of 85 ± 10%. Instead, testing was performed at ambient conditions within one minute of removal from the environmental chamber held at those parameters.

All test method acceptance criteria were met. Testing was performed in compliance with US FDA good manufacturing practice (GMP) regulations 21 CFR Parts 210, 211 and 820.

Number of Test Articles Tested:

Number of Test Articles Passed: 32

Test Side: Outside

Minimum of 4 hours at 21 \pm 5°C and 85 \pm 5% relative humidity (RH) Pre-Conditioning:

Test Conditions: 22.0°C and 22% RH

Results: Per ASTM F1862 and ISO 22609, an acceptable quality limit of 4.0% is met for a normal single sampling plan when ≥29 of 32 test articles show passing results.

Test Pressure: 160 mmHg (21.3 kPa)

Test Article Number

Synthetic Blood Penetration

1-32

None Seen





Study Director

James W. Luskin

01 APR 2020 Study Completion Date

sales@nelsonlabs.com

FRT0012-0002 Rev 13